Literature DB >> 22427327

Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.

Tobias Frank1, Florian Klinker, Björn H Falkenburger, Rico Laage, Fred Lühder, Bettina Göricke, Armin Schneider, Hartmud Neurath, Herbert Desel, David Liebetanz, Mathias Bähr, Jochen H Weishaupt.   

Abstract

Recent proof-of-principle data showed that the haematopoietic growth factor granulocyte colony-stimulating factor (filgrastim) mediates neuroprotection in rodent models of Parkinson's disease. In preparation for future clinical trials, we performed a preclinical characterization of a pegylated derivative of granulocyte colony-stimulating factor (pegfilgrastim) in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. We determined serum and cerebrospinal fluid drug levels after subcutaneous injection. A single injection of pegfilgrastim was shown to achieve stable levels of granulocyte colony-stimulating factor in both serum and cerebrospinal fluid with substantially higher levels compared to repetitive filgrastim injections. Leucocyte blood counts were only transiently increased after repeated injections. We demonstrated substantial dose-dependent long-term neuroprotection by pegfilgrastim in both young and aged mice, using bodyweight-adjusted doses that are applicable in clinical settings. Importantly, we found evidence for the functionally relevant preservation of nigrostriatal projections by pegfilgrastim in our model of Parkinson's disease, which resulted in improved motor performance. The more stable levels of pegylated neuroprotective proteins in serum and cerebrospinal fluid may represent a general advantage in the treatment of chronic neurodegenerative diseases and the resulting longer injection intervals are likely to improve patient compliance. In summary, we found that pegylation of a neuroprotective growth factor improved its pharmacokinetic profile over its non-modified counterpart in an in vivo model of Parkinson's disease. As the clinical safety profile of pegfilgrastim is already established, these data suggest that evaluation of pegfilgrastim in further Parkinson's disease models and ultimately clinical feasibility studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427327     DOI: 10.1093/brain/aws054

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  15 in total

Review 1.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

2.  pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.

Authors:  Pete Heinzelman; Jennifer A Schoborg; Michael C Jewett
Journal:  Protein Eng Des Sel       Date:  2015-04-15       Impact factor: 1.650

3.  The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.

Authors:  Aditi Dey; Yu Zhang; Anna Z Castleton; Katharine Bailey; Brendan Beaton; Bella Patel; Adele K Fielding
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

4.  Neurovascular unit crosstalk: Pericytes and astrocytes modify cytokine secretion patterns of brain endothelial cells.

Authors:  William A Banks; Andrej Kovac; Yoichi Morofuji
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-06       Impact factor: 6.200

5.  Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.

Authors:  Mariama S Azmy; Esther T Menze; Reem N El-Naga; Mariane G Tadros
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

Review 6.  Colony stimulating factors in the nervous system.

Authors:  Violeta Chitu; Fabrizio Biundo; E Richard Stanley
Journal:  Semin Immunol       Date:  2021-11-04       Impact factor: 11.130

7.  Neuroprotection of Granulocyte Colony-Stimulating Factor for Early Stage Parkinson's Disease.

Authors:  Sheng-Tzung Tsai; Sung-Chao Chu; Shu-Hsin Liu; Cheng-Yoong Pang; Ting-Wen Hou; Shinn-Zong Lin; Shin-Yuan Chen
Journal:  Cell Transplant       Date:  2016-12-07       Impact factor: 4.064

8.  Assessing blood granulocyte colony-stimulating factor as a potential biomarker of acute traumatic brain injury in mice and humans.

Authors:  William A Banks; Kenji Dohi; Kim Hansen; Hilaire J Thompson
Journal:  Brain Behav Immun       Date:  2015-10-09       Impact factor: 7.217

9.  Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor.

Authors:  Arathy S Kumar; Sankar Jagadeeshan; Anirudh Subramanian; Saravana Babu Chidambaram; Rohan Prasad Surabhi; Mahak Singhal; Hemadev Bhoopalan; Sathiya Sekar; Ravi Shankar Pitani; Prathiba Duvuru; Ganesh Venkatraman; Suresh K Rayala
Journal:  J Biol Chem       Date:  2016-04-04       Impact factor: 5.157

10.  Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.

Authors:  Lars Tönges; Tobias Frank; Lars Tatenhorst; Kim A Saal; Jan C Koch; Éva M Szego; Mathias Bähr; Jochen H Weishaupt; Paul Lingor
Journal:  Brain       Date:  2012-10-19       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.